Martin Horní

Martin Horní

Auto-generated profile, based on publicly available information

Martin Horní

Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MŠMichaela Šadibolová
Michaela Šadibolová
MHMartin Huličiak
Martin Huličiak
LSLucie Raisová Stuchlíková
Lucie Raisová Stuchlíková
MHMartin Horní
Martin Horní
LPLukáš Prchal
Lukáš Prchal
IBIva Boušová
Iva Boušová
6-prenylnaringenin (6-PN) has recently attracted attention for its chemopreventive, cytotoxic, and analgesic activities; however, information on its pharmacokinetic properties remains limited, making it difficult to interpret its biological effects. This study thus investigated the metabolism of 6-PN in humans, mice, and rats, as well as its intestinal transport and interaction with ABCB1 in humans. 6-PN (10 µM) was efficiently metabolized predominantly via phase II conjugation across all studied species. Overall, 13 phase I/II metabolites were detected, including novel sulfoglucuronide diconjugates not previously reported for structurally similar hop prenylflavonoids. Importantly, murine hepatic metabolism of 6-PN more closely resembled its human hepatic biotransformation profile, favoring murine over rat models in pharmacokinetics studied. Further, 6-PN showed appreciable transport in the absorptive AB direction, while the observed BA-over-AB asymmetry was not reduced by ABCB1/ABCG2 inhibition, although it modulated ABCB1 substrate transport in a model- and substrate-dependent manner. Overall, these data indicate that 6-PN can undergo transepithelial transport in the absorptive direction, whereas extensive phase II metabolism may substantially shape its bioavailability.